GILD Stock UPDATES Gilead Sciences (GILD) 112.00 11/02/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Gilead Sciences (GILD) 112.00 $GILD

5 Staggering Statistics About the Fastest Growing Drug in the World
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 01, 2:37PM CDT
Source: Flickr user Sergei Golyshev. In order for biotech companies to be successful they need to do two things very well: get drugs approved by the Food and Drug Administration and properly launch their approved drug. Even as recently as a...
JNJ: 107.78 (+0.74), VRTX: 112.64 (+1.79), GILD: 112.00 (-2.22), MRK: 57.94 (+0.63), ABBV: 63.46 (+2.28)

IBD 50 Caps Impressive 2-Week Rally
at Investor's Business Daily - Fri Oct 31, 5:47PM CDT
The IBD 50 just capped its best two-week performance in more than three years -- a run that's produced a batch of breakouts. The index rallied 9.4% over the past two weeks. That's the best two-week period since July 2011, when the IBD 50 roared...
ODFL: 72.87 (+0.51), AAP: 146.96 (+1.25), AKRX: 44.55 (+0.91), ILMN: 192.58 (-0.84), NXPI: 68.66 (+3.25), CDW: 30.84 (+0.71), CELG: 107.09 (+0.15), BIDU: 238.77 (+1.76), GILD: 112.00 (-2.22), JAZZ: 168.84 (-0.98), FLT: 150.56 (+8.01), FL: 56.01 (+0.16), AAPL: 108.00 (+1.02), AVGO: 86.25 (+3.86)

Final Glance: Biotechnology companies
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 112.00 (-2.22), AMGN: 162.18 (+0.60), CELG: 107.09 (+0.15)

Fundamentals, Technicals Still Intact At Gilead Sciences
at Investor's Business Daily - Fri Oct 31, 4:36PM CDT
Some analysts called Gilead Sciences' third-quarter earnings report on Oct. 28 "sloppy." But make no mistake: It's still a company in growth mode. And its weekly chart doesn't look bad either. Gilead's (GILD) earnings per share slightly missed...
GILD: 112.00 (-2.22)

Midday Glance: Biotechnology companies
AP - Fri Oct 31, 1:49PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 112.00 (-2.22), AMGN: 162.18 (+0.60), CELG: 107.09 (+0.15)

AbbVie Beats Q3 Earnings Estimates, Raises Guidance
at Investor's Business Daily - Fri Oct 31, 1:25PM CDT
Big pharma AbbVie beat analysts' Q3 estimates and raised its guidance Friday, sending its stock up 4% to an all-time high above 63. AbbVie's (ABBV) earnings rose 9% over the year-earlier quarter to 89 cents a share, 12 cents above analysts'...
IMS: 24.25 (+0.26), GILD: 112.00 (-2.22), SHPG: 199.80 (+0.38), AMGN: 162.18 (+0.60), ABBV: 63.46 (+2.28)

Early Glance: Biotechnology companies
AP - Fri Oct 31, 11:28AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 112.00 (-2.22), AMGN: 162.18 (+0.60), CELG: 107.09 (+0.15)

Stock Market News for October 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:10AM CDT
Benchmarks ended in the green zone on Thursday, banking on encouraging third quarter GDP numbers and upbeat quarterly results
JNJ: 107.78 (+0.74), NEE: 100.22 (+0.31), V: 241.43 (+4.78), GILD: 112.00 (-2.22), DUK: 82.15 (-0.14), EXC: 36.59 (-0.11), MRK: 57.94 (+0.63), PFE: 29.95 (+0.11), ABBV: 63.46 (+2.28), DTE: 82.16 (+0.17), SO: 46.36 (-0.09), MA: 83.75 (+0.62)

Gilead Sciences (GILD) Crosses Pivot Point Resistance at $115.51
Comtex SmarTrend(R) - Fri Oct 31, 8:58AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $113.06 today and have reached the first resistance level of $115.51. Should the shares continue to rise, the resistance pivots of $116.81 and $120.56 will be of interest.
GILD: 112.00 (-2.22)

Jim Cramer's Top Stock Picks: CELG REGN GILD BIIB TTWO CRL FLEX
at The Street - Fri Oct 31, 5:00AM CDT
Cramer says Take-Two Interactive is king of the hill and he's a big fan of Flextronics and its stock buyback program.
FLEX: 10.72 (+0.46), TTWO: 26.45 (+1.18), BIIB: 321.08 (+0.08), GILD: 112.00 (-2.22), CRL: 63.16 (+0.35), REGN: 393.72 (+0.92), CELG: 107.09 (+0.15)

Jim Cramer's 'Mad Money' Recap: Here's Why the Bears Were Dead Wrong
at The Street - Thu Oct 30, 7:11PM CDT
The end of quantitative easing was supposed to create a laundry list of problems, Cramer says. It didn't happen.
MMM: 153.77 (+1.67), BIIB: 321.08 (+0.08), HON: 96.12 (+0.53), FB: 74.99 (+0.88), BMY: 58.19 (-0.79), MGM: 23.25 (+0.27), ATK: 116.96 (+6.77), YRCW: 21.44 (+3.24), UPS: 104.91 (+1.62), SLB: 98.66 (+1.04), CELG: 107.09 (+0.15), WPRT: 6.17 (+0.12), SBUX: 75.56 (-1.76), TTWO: 26.45 (+1.18), DO: 37.71 (-0.94), ETP: 64.43 (+0.41), GILD: 112.00 (-2.22), ARR: 3.96 (-0.01), CMG: 638.00 (-1.68), MPEL: 27.14 (+0.78), WNC: 10.30 (+0.81), CRL: 63.16 (+0.35), AAPL: 108.00 (+1.02), REGN: 393.72 (+0.92)

5 Things McKesson Corporation's Management Wants You to Know
Keith Speights, The Motley Fool - Motley Fool - Thu Oct 30, 5:23PM CDT
Now that the dust has settled after McKesson Corporation 's second-quarter financial results were announced on Tuesday, it's time to look past the numbers. Yes, McKesson beat expectations for earnings and revenue -- but the real story is what's...
MCK: 203.41 (-0.07), GILD: 112.00 (-2.22), RAD: 5.25 (+0.07)

Netflix and Gilead Will See More Gains, Says Thornburg Value Manager
at The Street - Thu Oct 30, 4:54PM CDT
Gilead shares have had a tremendous run this year, but the valuation remains cheap considering its sales potential in the area of Hepatitis C.
NFLX: 392.77 (+13.76), PAHC: 25.92 (+0.27), GILD: 112.00 (-2.22)

Veeva Systems Flies High On Cloud For Life Sciences
at Investor's Business Daily - Thu Oct 30, 4:31PM CDT
Before founding software company Veeva Systems in 2007, Peter Gassner was certain of two things. He wanted the technology to be cloud-based and to address critical issues for a specific industry. He decided to focus on life sciences. "We could have...
VEEV: 29.78 (+0.99), IMS: 24.25 (+0.26), GILD: 112.00 (-2.22), MRK: 57.94 (+0.63), LLY: 66.33 (-0.47), ORCL: 39.05 (+0.55), CRM: 63.99 (+2.27), NVS: 92.69 (+0.74)

Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 3.13%
Comtex SmarTrend(R) - Thu Oct 30, 3:35PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $110.60 to a high of $114.35. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $114.13 on volume of 13.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 112.00 (-2.22)

SmarTrend Watching for Potential Pullback in Shares of Gilead Sciences After 3.13% Gain
Comtex SmarTrend(R) - Thu Oct 30, 3:34PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $110.60 to a high of $114.35. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $114.13 on volume of 13.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 112.00 (-2.22)

Most active Nasdaq-traded stocks
AP - Thu Oct 30, 12:17PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
MU: 33.09 (+1.27), GILD: 112.00 (-2.22), FB: 74.99 (+0.88), CDTI: 3.12 (-0.79), ARCP: 8.87 (-0.55), MSFT: 46.95 (+0.90), INTC: 34.01 (+1.43), GRPN: 7.31 (+1.32), AAPL: 108.00 (+1.02), CSCO: 24.47 (+0.39), RFMD: 13.01 (+0.94)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

AllyGPO Shines as Top Innovator in Health Tech

Updated Category News Views 0

Innovative Excellence in Healthcare Tech It's not every day you see a specialty group purchasing organization like AllyGPO snagging a spot on Fast Company's esteemed list of Best Workplaces for Innovators. Making it into the top half at number 40 in 2026, it’s a testament to a company really leaning into employee-driven innovation. And, buddy, this ain't just corporate...

Continue Reading
Regeneron Faces Class Action Over Tumultuous Trial Results

Updated Category News Views 3

Regeneron's Meltdown: A Bitter Pill for Investors Let’s dive headlong into the mess Regeneron Pharmaceuticals (NASDAQ:REGN) finds itself in—a classic nightmare scenario for investors. News broke like an old valve bursting, and suddenly, the market's love for Regeneron ran ice-cold. Who's to blame this time? Well, you might want to point a finger at the failed Phase 3...

Continue Reading
MADD, Uber Rally at Capital Invitational for Safe Choices

Updated Category News Views 0

Driving Change at the Capital Invitational Let's talk about a powerhouse collaboration aiming to do more than just thrill basketball fans. We're looking at MADD Sports, Uber, and the Capital Invitational joining forces at The St. James in Springfield, Virginia, on December 10, 2026. This is not your average sporting event; it's a gathering with a bigger purpose. The...

Continue Reading
SKF's Automotive Arm Set for Stockholm Debut in Dec

Updated Category News Views 4

The Big Spin-Off Play: SKF Vertevo So, SKF is at it again, pushing their Automotive business out the door as a newly minted public company—SKF Vertevo—on the horizon. It's like watching a mother bird kick the fledgling out of the nest. The Board's cooked up this spin-off strategy, and they're eyeing the Nasdaq Stockholm as the breeding ground, with the gears all set...

Continue Reading
Cultural Convergence: Ordos Event Captivates Global Visitors

Updated Category News Views 2

Ordos: Where Cultures Connect Seamlessly Spanning continents and cultures, the recent 'Warm City' event in Ordos, Inner Mongolia, drew international attention like bees to honey. Now, if you're thinking this is just another cultural shindig, think again. François Tchiegue, an ambassador of China-Africa cultural exchanges, described it best when he noted how the morin...

Continue Reading
CSG Powers Midwest Electrification, Eyes Energy Bridge

Updated Category News Views 7

Every now and again, a player like China Southern Power Grid steps up, making waves in the vast energy sea of the Asia-Pacific. The power company's latest foray, showcased at the Asia-Pacific Media Forum in Shenzhen, underscores its ambitions to beef up regional energy connectivity. Asia-Pacific's Hungry Energy Machine The Asia-Pacific region is no lightweight when it...

Continue Reading
Big Wins at Americas Cardroom's $15M Venom Series

Updated Category News Views 0

High Stakes and Huge Paydays: The Venom Breakdown Alright, folks, here's a tale of how the cards fell in one of the most electrifying poker standoffs at Americas Cardroom. With prize pools clocking in at a staggering $15.095 million, the Dual Mystery Bounty Venoms really stacked the chips high. From the gritty, bustling halls of the internet to the proverbial green-felt...

Continue Reading
Sony Meets Hello Kitty: A Collector's Audio Dream

Updated Category News Views 5

Unlikely Duo in Consumer Electronics It's time to listen up, and I mean literally. Who would've thunk it? Sony teams up with Hello Kitty for a limited-edition headphone collection that could make both audiophiles and pop-culture fanatics turn their heads faster than a rollercoaster. Now, I may have seen my fair share of wacky collaborations in my day, but the camaraderie...

Continue Reading
Verdafero Gains Ground in Sustainable Hospitality

Updated Category News Views 0

Verdafero's Latest Milestone: A Broader Environmental Reach It’s a day like today that makes you pause and realize that businesses in the hospitality space aren’t just about fluff and fancy lobbies anymore. They've got a new wave of responsibilities, especially with the globe pretty much on fire, literally and figuratively. Verdafero, a name not new to function and...

Continue Reading
Celebree Elevates Early Ed with New Certification Push

Updated Category News Views 0

A New Standard in Early Childhood Education In the cutthroat world of childcare and early education, just meeting the state standards ain't cutting it anymore. Celebree School, known for its infant, toddler, and preschool programs, is shaking things up with its 'Celebree Certified' initiative, setting a brand-new benchmark for teacher readiness that's far beyond the usual...

Continue Reading

Top 5 Most Recently Viewed Articles

Revitalizing Self-Care with White Lotus Beauty's Acupressure Set

Updated Category News Views 113

White Lotus Beauty: Pioneering Modern Wellness In today's fast-paced world, the concept of well-being is evolving. Self-care rituals are becoming essential for many as they seek tranquility amidst daily stress. Among the brands making waves in this wellness revolution is White Lotus Beauty, renowned for delivering Eastern-inspired beauty tools to a Western audience. Their...

Continue Reading
F.N.B. Corporation Supports Hurricane Relief with $100,000 Donation

Updated Category News Views 140

F.N.B. Corporation Steps Up for Hurricane Recovery Efforts F.N.B. Corporation (NYSE: FNB) has announced a generous donation of $100,000 to the American Red Cross. This initiative is aimed at providing essential support for recovery efforts in the aftermath of Hurricane Helene, which has impacted many communities. Commitment to Community Support According to Vincent J....

Continue Reading
Groupon, Inc. Faces Investor Scrutiny Amid Accounting Allegations

Updated Category News Views 215

Groupon, Inc. Faces Increased Investor Concerns Recent developments surrounding Groupon, Inc. (NASDAQ: GRPN) have sparked significant interest among investors and market analysts. As the company navigates allegations of questionable accounting practices, many are questioning the integrity of its reported financial results. The Investigation Details Pomerantz LLP is...

Continue Reading
Mowi's Strategic Acquisition of Nova Sea Marks Growth Phase

Updated Category News Views 253

Mowi’s Strategic Acquisition of Nova Sea Approved Mowi ASA has successfully acquired a controlling stake in Nova Sea AS, marking a significant step in its growth strategy. This acquisition has gained final approval from necessary authorities, providing Mowi with an enhanced footprint in the seafood industry. The Transaction Approval Process Initially disclosed in a...

Continue Reading
Sanofi's Strategic Move to Enhance Adult Vaccination Pipeline

Updated Category News Views 94

Sanofi Strengthens Its Vaccination Portfolio Sanofi SA (NASDAQ: SNY) has made a significant step in the healthcare sector by acquiring Dynavax Technologies Corporation (NASDAQ: DVAX) for approximately $2.2 billion. This acquisition, which involves a cash purchase price of $15.50 per share, signals Sanofi's commitment to enhancing its capabilities in the adult immunization...

Continue Reading